STOCK TITAN

Delcath Systems Inc - DCTH STOCK NEWS

Welcome to our dedicated news page for Delcath Systems (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Systems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Delcath Systems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Delcath Systems's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.03%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Delcath Systems Inc

Nasdaq:DCTH

DCTH Rankings

DCTH Stock Data

125.92M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular